scholarly journals Astrocytic S100B, Blood-Brain Barrier and Neurodegenerative Diseases

2020 ◽  
Author(s):  
Anuradha Krishnan ◽  
Hao Wu ◽  
Venkat Venkataraman
Keyword(s):  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain

Nanotechnology: its application in treating Neurodegenerative diseases

2020 ◽  
Vol 19 ◽  
Author(s):  
Falaq Naz ◽  
Yasir Hasan Siddique
Keyword(s):  
Quality Of Life ◽  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Huntington Disease ◽  
Treatment Strategies ◽  
Present Review ◽  
Brain Barrier ◽  
Treatment Level ◽  
Blood Brain

: Neurodegenerative diseases including Alzheimer’s, Parkinson’s and Huntington disease are have serious concern due to its effect on the quality of life of affected persons. Neurodegenerative diseases have some limitations for both diagnostic as well as at treatment level. Introducing nanotechnology, for the treatment of these diseases may contribute significantly in solving the problem. There are several treatment strategies for the neurodegenerative diseases, but their limitations are the entry into the due to the presence of the blood-brain barrier (BBB). The present review highlights the application of nanotechnology during last 20 years for the treatment of neurodegenerative diseases.

scholarly journals Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier

Biochimie ◽  
2020 ◽  
Vol 170 ◽  
pp. 203-211 ◽  
Author(s):  
Mayssa Hachem ◽  
Mounir Belkouch ◽  
Amanda Lo Van ◽  
Madeleine Picq ◽  
Nathalie Bernoud-Hubac ◽  
...  
Keyword(s):  
Docosahexaenoic Acid ◽  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Brain Targeting ◽  
Blood Brain

scholarly journals Building a better blood-brain barrier

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Courtney Lane-Donovan ◽  
Joachim Herz
Keyword(s):  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Three Dimensional ◽  
Brain Barrier ◽  
Dimensional Model ◽  
Three Dimensional Model ◽  
Blood Brain

A new three-dimensional model of the blood-brain barrier can be used to study processes that are involved in neurodegenerative diseases.

scholarly journals Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases

2016 ◽  
Vol 235 ◽  
pp. 34-47 ◽  
Author(s):  
Cláudia Saraiva ◽  
Catarina Praça ◽  
Raquel Ferreira ◽  
Tiago Santos ◽  
Lino Ferreira ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Brain Drug Delivery ◽  
Blood Brain

scholarly journals Blood-brain barrier opening for facilitating drug delivery in neurological and neurodegenerative diseases in non-human primates

2018 ◽  
Author(s):  
Elisa E. Konofagou
Keyword(s):  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Focused Ultrasound ◽  
Neurological Diseases ◽  
Brain Barrier ◽  
Blood Brain ◽  
Therapeutic Molecules ◽  
After Cancer ◽  
Large Animals

After cancer and heart disease, neurodegenerative diseases, such as Alzheimer's, Parkinson's, multiple sclerosis (MS), amythrophic lateral sclerosis (ALS), and neurological diseases take more lives each year than any other illness. Although great progress has been made in recent years toward understanding of central nervous system (CNS) diseases, few effective treatments and no cures are currently available. This is mainly because the blood-brain barrier (BBB) limits the delivery of the vast majority of systemically-administered drugs available to treat those diseases. The underlying hypothesis of this study is that delivery of therapeutic molecules is safe and effective through the blood-brain barrier (BBB) using Focused Ultrasound (FUS) in large animals in vivo. Our preliminary results have shown that the FUS technique can induce BBB opening entirely noninvasively, selectively and be monitored with MRI at sub-millimeter resolution in vivo. The specific aims are therefore to: 1) build a MRcompatible system for FUS targeting and monitoring in the MRI system; 2) test and demonstrate delivery of neurotrophic factors to the hippocampus and putamen of monkeys; 3) test and demonstrate delivery of inhibitors to the visual cortex of monkeys; and 4) assess the safety of the FUS method in monkeys.

scholarly journals Altered Blood-Brain Barrier and Blood-Spinal Cord Barrier Dynamics in Amyotrophic Lateral Sclerosis: Impact on Medication Efficacy and Safety

2021 ◽  
Author(s):  
Yijun Pan ◽  
Joseph Nicolazzo
Keyword(s):  
Spinal Cord ◽  
Amyotrophic Lateral Sclerosis ◽  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Large Body ◽  
Brain Barrier ◽  
Blood Brain ◽  
Blood Spinal Cord Barrier ◽  
The Brain ◽  
Lateral Sclerosis

The access of drugs into the central nervous system (CNS) is regulated by the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB). A large body of evidence supports perturbation of these barriers in neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Modifications to the BBB and BSCB are also reported in amyotrophic lateral sclerosis (ALS), albeit these modifications have received less attention relative to those in other neurodegenerative diseases. Such alterations to the BBB and BSCB have the potential to impact on CNS exposure of drugs in ALS, modulating the effectiveness of drugs intended to reach the brain and the toxicity of drugs that are not intended to reach the brain. Given the clinical importance of these phenomena, this review will summarise reported modifications to the BBB and BSCB in ALS, discuss their impact on CNS drug exposure and suggest further research directions so as to optimise medicine use in people with ALS.

scholarly journals Pathomechanisms of Blood-Brain Barrier Disruption in ALS

2019 ◽  
Vol 2019 ◽  
pp. 1-16 ◽  
Author(s):  
Nicholas Kakaroubas ◽  
Samuel Brennan ◽  
Matthew Keon ◽  
Nitin K. Saksena
Keyword(s):  
Neurodegenerative Diseases ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain Barrier Disruption ◽  
Blood Brain ◽  
Neurological Processes ◽  
Brain Barrier Disruption ◽  
Pass Through ◽  
Blood Spinal Cord Barrier ◽  
Novel Therapeutic Strategies

The blood-brain barrier (BBB) and the blood-spinal cord barrier (BSCB) are responsible for controlling the microenvironment within neural tissues in humans. These barriers are fundamental to all neurological processes as they provide the extreme nutritional demands of neural tissue, remove wastes, and maintain immune privileged status. Being a semipermeable membrane, both the BBB and BSCB allow the diffusion of certain molecules, whilst restricting others. In amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, these barriers become hyperpermeable, allowing a wider variety of molecules to pass through leading to more severe and more rapidly progressing disease. The intention of this review is to discuss evidence that BBB hyperpermeability is potentially a disease driving feature in ALS and other neurodegenerative diseases. The various biochemical, physiological, and genomic factors that can influence BBB permeability in ALS and other neurodegenerative diseases are also discussed, in addition to novel therapeutic strategies centred upon the BBB.

Sign in / Sign up

Export Citation Format

Share Document